StockData

NewAmsterdam Pharma vs Xenon Pharmaceuticals

NAMS and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and XENE compare

NewAmsterdam Pharma grew revenue faster over the last twelve months (−88.9% versus −100% for Xenon Pharmaceuticals).

Xenon Pharmaceuticals scores higher on the StockData Score (7 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSXENE
Size and price
Market cap–$3.8B
Share price$19.39$38.78
Change, 1 year−49.4%−4.9%
Change, 5 years98.1%41.3%
Beta (5Y)1.570.26
Employees100370
StockData Score
Total score67 (better)
Valuation score00
Growth score00
Performance score11
Health score56 (better)
Dividend score00
Valuation
P/B–3.0×
FCF yield–−9.0%
Growth
Revenue growth (TTM)−88.9% (better)−100%
Revenue growth, 5Y average–−25.3%
Profitability
Operating margin−3432%–
Net margin−3644%–
FCF margin−2018%–
Return on equity−36.8% (better)−43.6%
Return on invested capital−1046%−152% (better)
Financial health
Debt / equity0.000.00
Current ratio9.0321.02 (better)
Altman Z-score–40.35
Piotroski F-score33
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–104%
Held by insiders22.0%0.17%
Insider net buying, 12 months−$63.0M−$20.3M (better)
Superinvestors holding–1
Short interest, % of float–7.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.